Inactive Instrument

Parabolic Drugs Limited Stock price NSE India S.E.

Equities

PARABDRUGS

INE618H01016

Pharmaceuticals

Dynamic Chart
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended 31 December, 2020 CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Quarter and Half Year Ended September 30, 2020 CI
Parabolic Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2019 CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended March 31, 2020 CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Quarter Ended September 30, 2018 CI
Parabolic Extends Submission Date For EOI’s CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Second Quarter and Half Year Ended September 30, 2018 CI
Parabolic Drugs Limited Announces Unaudited Earnings Results for the Quarter Ended June 30, 2018 CI
Parabolic Drugs Limited Announces Change of Registered/Corporate Office CI
Parabolic Drugs Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Audited Standalone and Consolidated Earnings Results for the Year Ended March 31, 2018 CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017 CI
Parabolic Drugs Limited Announces Executive Changes CI
Parabolic Drugs Limited Announces Executive Changes CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2017 CI
Parabolic Drugs Ltd. Announces Unaudited Earnings Results for First Quarter Ended June 30, 2017 CI
More news
Managers TitleAgeSince
Founder 57 95-12-31
Director of Finance/CFO - 17-05-09
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 54 -
Founder 57 95-12-31
Chairman 73 -
More insiders
Parabolic Drugs Limited is a holding company. The Company is an integrated, research-based, pharmaceutical manufacturer and exporter, engaged in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates. It is engaged in the manufacture of pharmaceuticals, medicinal chemical and botanical products. Its products and services include Cefuroxime Axetil Amorphus and Ceftriaxone Sodium Sterile. Its product portfolio includes Oral and Sterile Semi Synthetic Penicillin API, Oral and Sterile Cephalosporin API in antibiotic segment to non-antibiotic API in the Cardiovascular, Nonsteroidal anti-inflammatory drugs (NSAID), Anti-Hypertensive and Osteoporosis segments. Its products include Cefixime Trihydrate, Ceftibuten, Cefcapene Pivoxil, Cefuroxime Sodium, Amoxycillin Trihydrate, Bacampicillin Hcl, Piperacillin Sodium, Sulbactum Sodium, Deferasirox, Pentazocine, Raubasine, Yohimbine, Montelukast, Vildagliptin, Cefoxitin Sodium and Cefpodoxime Acid.
More about the company
  1. Stock
  2. Equities
  3. Stock Parabolic Drugs Limited
  4. Stock Parabolic Drugs Limited - NSE India S.E.